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Objective: The prevalence of signiﬁcant comorbidities among patients with abdominal aortic aneurysms (AAAs) has
contributed to widespread enthusiasm for endovascular AAA repair (EVAR). However, the advantages of EVAR in
patients at low risk for open surgical repair (OSR) remain unclear. The objective of this study was to assess perioperative
outcomes of EVAR and OSR in low-risk patients.
Methods: Patients undergoing EVAR and OSR for infrarenal AAAs were identiﬁed in the 2007 to 2010 National Surgical
Quality Improvement Program data sets. AAA-speciﬁc risk stratiﬁcation, by the Medicare aneurysm scoring system, was
used to create matched low-risk (score <3) cohorts. Perioperative morbidity and mortality were assessed by crude
comparisons of matched groups and regression models.
Results:Of 11,753 elective patients undergoing EVAR, 4339 (37%) were deemed low risk (score <3). A matched cohort of
1576 low-risk patients was developed from a total of 3804 (41%) undergoing OSR. The low-risk cohorts included only
male patients and those <75 years of age, without signiﬁcant cardiac, pulmonary, or vascular comorbidities. Mean age
in both low-risk groups was 67 6 6 years (P[ NS). EVAR patients had higher rates of obesity (40% vs 33%; P < .001),
diabetes (16% vs 13%; P [ .005), history of cardiac intervention (24% vs 19%; P < .001), cardiac surgery (23% vs 20%;
P[ .02), steroid use (4% vs 2%; P[ .002), and bleeding disorders/anticoagulation (9% vs 6%; P[ .001) compared with
OSR patients. There were no other differences between the matched cohorts. EVAR was associated with reduced 30-day
mortality (0.5% vs 1.5%; P < .01) and reduced rates of major complications, including the following: sepsis (0.7% vs 3.2%;
P < .01), unplanned intubation (1.0 vs 5.4%; P < .001), pneumonia (0.8% vs 6.1%; P < .001), acute renal failure (0.4% vs
2.7%; P < .001), and early reoperation (3.7% vs 6.0%; P < .001). Furthermore, EVAR was associated with reduced
perioperative morbidity across organ systems, including venous thromboembolism (0.1% vs 0.3%; P[ .001), transfusion
requirement of more than 4 units (2.0% vs 13.0%; P < .001), cardiac arrest (0.2 vs 0.8; P [ .001), neurologic deﬁcits
(0.2% vs 0.5%; P [ .032), and urinary tract infections (1.2% vs 2%; P [ .02).
Conclusions: Our results demonstrate that even among those male patients at low risk for OSR on the basis of comor-
bidities, EVAR is associated with reduced perioperative mortality and major complications. Whereas clinical decisions
must account for safety and long-term effectiveness, the short-term beneﬁt of EVAR is evident even among male patients
at the lowest risk for OSR. (J Vasc Surg 2014;60:1154-8.)Since 2006, endovascular repair (EVAR) of abdominal
aortic aneurysms (AAAs) has outpaced open surgical repair
(OSR), with more than 70% of AAAs now repaired by
EVAR.1,2 Despite persistent concerns about long-term
durability, enthusiasm for EVAR is driven by the reduced
early morbidity associated with this less invasive technique,
particularly in light of the high prevalence of signiﬁcant
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4has been associated with improved early outcomes in
comparison with OSR.3,4 Furthermore, on a population
level, the increased use of EVAR has been associated with
lower short-term AAA-related mortality and fewer aneu-
rysms presenting with rupture.1 High-risk and elderly
patients, in particular, have been shown to beneﬁt with
EVAR compared with OSR in regard to perioperative com-
plications and mortality.2-6
However, the beneﬁt of EVAR over OSR in patients
who are at low risk for perioperative morbidity and mortal-
ity remains unclear. Whereas the superiority of minimally
invasive treatments such as EVAR may provide an obvious
short-term beneﬁt for high-risk patients, vascular specialists
continue to debate the appropriateness of EVAR in
patients who are suitable candidates for OSR who could
be expected to tolerate OSR. In fact, low-risk patients
may be preferentially offered open repair, particularly if
vascular specialists believe the favorable durability of OSR
overshadows any short-term beneﬁt of EVARdif it even
existsdin patients at low risk for perioperative complica-
tions.2,7-9 To address these considerations, we used the
American College of Surgeons National Surgical Quality
Table I. Medicare aneurysm scoring system10
Risk factor Score
Age >80 years 11
Age 76-80 years 6
Age 71-75 years 1
Female 4
ESRD 9
CRI, no dialysis 7
CHF 6
PVD or CBVD 3
CBVD, Cerebrovascular disease; CHF, congestive heart failure; CRI,
chronic renal insufﬁciency; ESRD, end-stage renal disease; PVD, peripheral
vascular disease.
High risk, >11; moderate risk, 3-11; low risk, <3.
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perioperative outcomes of EVAR with those of OSR in
low-risk patients. We hypothesized that the perceived
short-term beneﬁts of EVAR vs OSR would be demon-
strable in this low-risk cohort.
METHODS
Patients undergoing elective EVAR and OSR for
infrarenal AAAs were identiﬁed in the 2007 to 2010NSQIP
data sets. AAA-speciﬁc risk stratiﬁcation, by the Medicare
aneurysm scoring system, was used to create matched low-
risk cohorts (Table I).10 Institutional Review Board
approval was obtained and patient consent was waived.
Medicare aneurysm scoring system. The Medicare
aneurysm score was developed as a risk prediction tool
for perioperative mortality speciﬁc to AAA repair. Derived
form Medicare data of all patients undergoing both intact
EVAR and OSR of AAA, the scoring system facilitates
risk prediction based on preoperative characteristics appli-
cable to patients undergoing both EVAR and OSR.10
Variables included in the model are age and gender and
the presence of congestive heart failure, peripheral vascular
disease, chronic renal insufﬁciency, and cerebrovascular
disease; points are assigned on the basis of the degree of
inﬂuence on the risk. After assignment of a cumulative
point score, patients may be risk stratiﬁed into low-,
moderate-, and high-risk categories for perioperative
mortality (Table I). Female gender in the model is assigned
a score of 4; therefore, no female patients are low risk
(score <3). Analysis of the low-risk groups contains only
male patients.
ACS NSQIP. The ACS NSQIP program is a prospec-
tive, multicenter database with risk-adjusted outcomes for
quality improvements. Details pertaining to data gathering,
sampling, and structure of the participant use ﬁles have
been previously described.10-12 The ACS NSQIP includes
perioperative data with >135 variables, including patient
characteristics, preoperative risk factors, intraoperative
variables, and 30-day postoperative complications and
mortality for speciﬁed surgical procedures.
Database development and scoring. All patients
undergoing infrarenal AAA repair without visceral or renalinvolvement by EVAR or OSR were identiﬁed by the ACS
NSQIP during a 4-year period from 2007 to 2010.
Infrarenal AAA repairs were identiﬁed by Current Proce-
dural Terminology (CPT, American Medical Association,
Chicago, IL) codes 34800, 34802, 34803, 34804, 34805,
35081, and 35102. Patients with additional CPT codes
suggesting more complex aneurysms with visceral
involvement (35091, 35092) or with concomitant bypass
grafts to the renal or visceral vessels (35531, 35560,
35535, 35536, 35631, 35632, 35633, 35634, 35636)
were excluded from the analysis.
Demographic variables examined included age, sex,
race, and smoking history. Preoperative functional status
(independent, partially dependent, and totally dependent)
assesses the patient’s ability to perform activities of daily
living before the operation. Medical conditions included
diabetes mellitus, severe chronic obstructive pulmonary
disease, congestive heart failure, hypertension, peripheral
vascular disease requiring prior revascularization or ampu-
tation, altered mental status, prior steroid use, bleeding
disorders/chronic anticoagulation, hemodialysis depen-
dence, prior percutaneous coronary intervention, prior
cardiac surgery, current angina or myocardial infarction
6 months before surgery, prior stroke with or without
deﬁcits, do not resuscitate status, and presence of a
wound or infection. Speciﬁc details of the aortic aneu-
rysm, aside from visceral involvement, are not variables
in the NSQIP.
Bivariate analysis was performed to compare outcomes
between EVAR and OSR. Categorical variables were
compared by Pearson c2 tests, and distributions of contin-
uous variables were compared by Wilcoxon rank sum tests.
To facilitate analysis speciﬁcally of low-risk patients,
NSQIP-captured variables were used to derive the Medi-
care aneurysm score for each patient, and only those in
the lowest risk group for perioperative mortality
(score <3) were included in the analysis.
RESULTS
There were 11,753 patients who underwent elective
endovascular repair and 3804 patients who underwent
open repair of infrarenal AAA without visceral involvement
from 2007 to 2010. Of these, 4339 patients (37%) under-
going EVAR were low risk by the Medicare aneurysm
scoring system, whereas 1576 patients (41%) undergoing
OSR were low risk. These cohorts included only men,
those aged <75 years, and those without a history of
congestive heart failure, chronic renal insufﬁciency, periph-
eral vascular disease, or cerebrovascular disease. Mean age
in both low-risk groups was 67 6 6 years. Comorbidities
in each group are listed in Table II. These low-risk male
EVAR patients had a higher rate of comorbidities overall,
speciﬁcally obesity, previous coronary disease, steroid use,
and bleeding disorders/chronic anticoagulation.
EVAR was associated with lower 30-day mortality
(0.5% vs 1.5%; P < .01) compared with OSR. Moreover,
EVAR was associated with reduced perioperative morbidity
across organ systems. These included lower pulmonary,
Table II. Patient characteristics and comorbidities
Covariate Total, No. (%) EVAR, No. (%) OSR, No. (%) P value
Total 5527 4068 1459 N/A
Nonwhite 780 (14) 561 (14) 219 (21) .25
White 4747 (86) 3507 (86) 1240 (79)
Body mass index <.001
Normal 1137 (21) 760 (19) 377 (26)
Underweight 68 (1) 46 (1) 22 (2)
Overweight 2135 (39) 1572 (39) 563 (39)
Obese 2119 (38) 1637 (40) 482 (33)
Presurgery functional health status .23
Independent 5433 (99) 4005 (98) 1428 (98)
Partial dependence 80 (1) 55 (1) 25 (2)
Total dependence 14 (<1) 8 (<1) 6 (<1)
Diabetes () 4678 (85) 3410 (84) 1268 (87) .05
Diabetes (þ) 849 (15) 658 (16) 191 (13)
Steroid use () 5351 (97) 3921 (96) 1430 (98) .002
Steroid use (þ) 176 (3) 147 (4) 29 (2)
Weight loss () 5472 (99) 4029 (99) 1443 (99) .65
Weight loss (þ) 55 (1) 39 (1) 16 (1)
Bleeding disorder/anticoagulation () 5088 (92) 3715 (91) 1375 (94) .001
Bleeding disorder/anticoagulation (þ) 439 (8) 353 (9) 84 (6)
COPD () 4545 (82) 3340 (83) 1205 (82) .68
COPD (þ) 982 (18) 728 (17) 254 (18)
Prior PCI () 4257 (77) 3078 (76) 1179 (81) <.001
Prior PCI (þ) 1270 (23) 990 (24) 280 (19)
Prior cardiac surgery () 4318 (78) 3147 (77) 1171 (80) .021
Prior cardiac surgery (þ) 1209 (22) 921 (23) 288 (20)
Recent MI () 5467 (99) 4024 (99) 1443 (99) .96
Recent MI (þ) 60 (1) 44 (1) 16 (1)
Hypertension () 1248 (23) 925 (23) 323 (22) .64
Hypertension (þ) 4279 (77) 3143 (77) 1136 (78)
COPD, Chronic obstructive pulmonary disease; EVAR, endovascular aneurysm repair; N/A, not applicable; MI, myocardial infarction; OSR, open surgical
repair; PCI, percutaneous coronary intervention.
Table III. Systemic complications
Complications Total, No. (%) EVAR, No. (%) OSR, No. (%) P value
Total 5527 4068 1459 N/A
Mortality, 30-day 46 (0.8) 24 (0.5) 22 (1.5) .001
Return to the OR within 30 days 239 (4.3) 151 (3.7) 88 (6.0) <.001
Deep venous thrombosis 30 (0.5) 14 (0.3) 16 (1.1) .001
Graft complications 35 (0.6) 29 (0.7) 6 (0.4) .21
Postoperative blood transfusion 28 (0.5) 8 (0.2) 20 (1.4) <.001
Myocardial infarction 39 (0.7) 18 (0.4) 21 (1.4) <.001
Cardiac arrest 20 (0.4) 8 (0.2) 12 (0.8) <.001
Neurologic deﬁcit 16 (0.3) 8 (0.2) 8 (0.5) .032
Stroke 8 (0.1) 5 (0.1) 3 (0.2) .48
Acute renal failure 54 (1.0) 15 (0.4) 39 (2.7) <.001
Postoperative intubation >48 hours 130 (2.4) 26 (0.6) 104 (7.1) <.001
Pulmonary embolism 16 (0.3) 10 (0.2) 6 (0.4) .31
Unplanned reintubation 120 (2.2) 41 (0.1) 79 (5.4) <.001
EVAR, Endovascular aneurysm repair; N/A, not applicable; OR, operating room; OSR, open surgical repair.
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Infectious and wound complications were lower in EVAR
compared with OSR, with less pneumonia, sepsis, septic
shock, urinary tract infections, and wound dehiscence
(Table IV). There were also fewer reoperations within
30 days in the EVAR group. There was no difference
seen for graft complications, stroke, pulmonary embolism,
or superﬁcial or deep surgical site infections. Nocomplications were more prevalent in the EVAR group.
Median length of stay in the EVAR group was 1 day
compared with 6 days with OSR (P < .001).
DISCUSSION
Our results demonstrate that EVAR is associated with
reduced perioperative mortality and major morbidity
compared with OSR in low-risk male patients.
Table IV. Infectious complications
Complications Total, No. (%) EVAR, No. (%) OSR, No. (%) P value
Superﬁcial SSI 82 (1.5) 56 (1.4) 26 (1.8) .27
Deep SSI 26 (0.5) 9 (0.2) 17 (1.2) .341
Organ space SSI 12 (0.2) 4 (0.1) 8 (0.5) .002
Wound dehiscence 34 (0.6) 8 (0.2) 26 (1.8) <.001
Pneumonia 122 (2.2) 33 (0.8) 89 (6.1) <.001
Urinary tract infection 76 (1.4) 47 (1.2) 29 (2.0) .02
Sepsis 74 (1.3) 27 (0.7) 47 (3.2) <.001
Septic shock 51 (0.9) 35 (0.9) 16 (1.1) <.001
EVAR, Endovascular aneurysm repair; OSR, open surgical repair; SSI, surgical site infection.
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repair in this low-risk population. Complications that
were more common with OSR included multiple organ
systems: pulmonary, cardiac, renal, hematologic, and geni-
tourinary. Perioperative unplanned return to the operating
room was also signiﬁcantly higher in the OSR group, as was
median postoperative length of stay. Infectious complica-
tions including pneumonia, urinary tract infection, sepsis,
and septic shock were also higher with OSR. These ﬁnd-
ings are particularly striking when one considers that
despite an effort to match cohorts by the Medicare aneu-
rysm scoring system, patients in the EVAR group had
higher rates of diabetes, obesity, steroid use, coagulation
disorders/chronic anticoagulation, and previous percuta-
neous and open cardiac interventions compared with pa-
tients in the OSR group. This ﬁnding reafﬁrms the
superior short-term outcomes of EVAR. The superior
safety proﬁle of EVAR, compared with OSR, has previously
been established for the overall population.2,3 This beneﬁt
has been particularly shown to extend to high-risk patients
and those with advanced age.2,3 Most vascular specialists
would agree that for patients at increased risk for adverse
perioperative events, the favorable safety proﬁle of EVAR
supersedes the durability of OSR.2,3 The minimally invasive
nature of EVAR led to its rapid adoption and dissemina-
tion. Whereas the beneﬁt of EVAR in high-risk patients is
self-evident, the optimal management of patients with
AAA who are at “low risk” for OSR remained controver-
sial, and it remained unclear if EVAR was justiﬁabledon
the grounds of favorable short-term outcomesdin patients
at low risk for OSR. We used the NSQIP database to assess
early outcomes and perioperative morbidity and mortality
because the beneﬁt of EVAR hinges on favorable perioper-
ative outcomes.
The objective of this retrospective study was not to
assess long-term outcomes between the two treatment
modalities. The long-term durability of OSR is beyond
repute, and even endovascular enthusiasts must concede
that there are insufﬁcient data with the current incarnation
of devices for EVAR to compare with the decades of expe-
rience with OSR. As the beneﬁt of EVAR remains periop-
erative outcomes, understanding of short-term outcomes
has a critical role in clinical decision making.2,5,11 Clinical
decisions must account for the long-term safety and effec-
tiveness of EVAR compared with OSR; these need to beevaluated on the basis of the individual case and will
need to be re-evaluated as the technology changes.
Long-term comparison of EVAR with OSR remains
unclear. There is variation in the literature; some studies
show improved long-term survival with EVAR compared
with OSR despite treatment of an overall healthier,
younger population with OSR, and others show equal
long-term survival.13-17 Data supporting long-term beneﬁt
and durability of EVAR include the Open vs Endovascular
Repair (OVER) trial, which showed no difference in overall
survival at 9 years with an increased long-term survival
beneﬁt in patients younger than 70 years. However, there
were more aneurysm-related deaths in the EVAR group,
but overall numbers were low.13 The goal of this study
was not to assess this but rather to address the perioperative
outcomes. The improved perioperative outcomes with
EVAR in the low-risk patient population seen here need
to be balanced with the long-term risks for reintervention
and durability of the repair. However, we have demon-
strated that it is not appropriate simply to assume that
the perioperative risks are equal between EVAR and OSR
for the lowest risk male patients.
Limitations of this study include those inherent to use
of a large national database. However, one of the main
advantages of the NSQIP database is that it offers indepen-
dent adjudication of 30-day outcomes by an impartial
party, namely, a trained clinical nurseereviewer, that has
been previously validated. In addition, only those patients
who were deemed “ﬁt” by vascular surgeons were included
in the database, leading to an inherent selection bias.
NSQIP does not provide us with long-term outcomes,
although that is not the objective of this paper. Also,
NSQIP does not include every patient at every partici-
pating center; however, it randomly samples patients to
obtain an accurate assessment. Another limitation is that
we cannot stratify by region or center to take into account
volume-outcome relationships. Because the diagnosis was
based on CPT codes, despite efforts to exclude those cases
with visceral segment involvement, aneurysm characteris-
tics other than important clinical parameters such as aneu-
rysm size and clamp location cannot be ascertained from
this data set. The Medicare aneurysm model assigns
4 points for female gender, and low risk was deﬁned
as <3 points (Table I).10 No female patients are considered
low risk in this model, and therefore a low-risk comparison
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our analysis applicable only to male patients. Finally, the
overall absolute rates of mortality and signiﬁcant complica-
tions are low, raising the issue of effect size in a study such
as this. However, it is noteworthy that in many cases, the
difference not only was statistically signiﬁcant but repre-
sents a several-fold difference between the two groups.
CONCLUSIONS
Our results from a national registry demonstrate that
even among those patients at lowest risk in regard to their
comorbidities for OSR, EVAR is associated with reduced
perioperative mortality and major complications. Whereas
clinical decisions must account for safety and long-term
effectiveness, the short-term beneﬁt of EVAR in low-risk
male patients is evident compared with OSR.
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